419 related articles for article (PubMed ID: 35265666)
1. Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response.
Tong W; Wang G; Zhu L; Bai Y; Liu Z; Yang L; Wu H; Cui T; Zhang Y
Front Mol Biosci; 2021; 8():793445. PubMed ID: 35265666
[No Abstract] [Full Text] [Related]
2. CD93 Correlates With Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
Zhang Z; Zheng M; Ding Q; Liu M
Front Cell Dev Biol; 2022; 10():817965. PubMed ID: 35242761
[No Abstract] [Full Text] [Related]
3. Multi-omics profiling and digital image analysis reveal the potential prognostic and immunotherapeutic properties of CD93 in stomach adenocarcinoma.
Wu B; Fu L; Guo X; Hu H; Li Y; Shi Y; Zhang Y; Han S; Lv C; Tian Y
Front Immunol; 2023; 14():984816. PubMed ID: 36761750
[TBL] [Abstract][Full Text] [Related]
4. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
5. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
6. Identify the immune characteristics and immunotherapy value of CD93 in the pan-cancer based on the public data sets.
Guo A; Zhang J; Tian Y; Peng Y; Luo P; Zhang J; Liu Z; Wu W; Zhang H; Cheng Q
Front Immunol; 2022; 13():907182. PubMed ID: 36389798
[TBL] [Abstract][Full Text] [Related]
7. Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis.
Ye Y; Jiang H; Wu Y; Wang G; Huang Y; Sun W; Zhang M
Front Mol Biosci; 2022; 9():1001225. PubMed ID: 36213111
[No Abstract] [Full Text] [Related]
8. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
[TBL] [Abstract][Full Text] [Related]
10. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
Front Genet; 2022; 13():993438. PubMed ID: 36685895
[No Abstract] [Full Text] [Related]
12. Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy.
Lin Z; Wu Y; Xiao X; Zhang X; Wan J; Zheng T; Chen H; Liu T; Tang X
Front Genet; 2022; 13():938510. PubMed ID: 36171879
[No Abstract] [Full Text] [Related]
13. Comprehensive Analysis of
Liu J; Zhu B; Chen J; Cao Y
Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
[TBL] [Abstract][Full Text] [Related]
14. A Pan-Cancer Analysis Revealing the Dual Roles of Lysine (K)-Specific Demethylase 6B in Tumorigenesis and Immunity.
Ding JT; Yu XT; He JH; Chen DZ; Guo F
Front Genet; 2022; 13():912003. PubMed ID: 35783266
[No Abstract] [Full Text] [Related]
15. Identification and validation of
Li L; Li F; Xu Z; Li L; Hu H; Li Y; Yu S; Wang M; Gao L
Front Pharmacol; 2023; 14():1213891. PubMed ID: 37680718
[No Abstract] [Full Text] [Related]
16. The Role of NCS1 in Immunotherapy and Prognosis of Human Cancer.
Wang GC; Gan X; Zeng YQ; Chen X; Kang H; Huang SW; Hu WH
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893139
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
18. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
19. CD93 serves as a potential biomarker of gastric cancer and correlates with the tumor microenvironment.
Li Z; Zhang XJ; Sun CY; Fei H; Li ZF; Zhao DB
World J Clin Cases; 2023 Feb; 11(4):738-755. PubMed ID: 36818626
[TBL] [Abstract][Full Text] [Related]
20. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L
Front Immunol; 2023; 14():1158360. PubMed ID: 37483608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
